iNCOVACC, worlds first nasal Covid-19 vaccine manufactured by Bharat Biotech, approved for emergency use

Nasal Covid-19 vaccine iNCOVACC: Hyderabad based biotechnology company Bharat Biotech has launched the world's first nasal Covid-19 vaccine. According to a Tweet shared by Bharat Biotech on Monday evening, iNCOVACC recently received approval under Restricted Use in Emergency Situation for ages 18 and above for heterologous booster doses.

In heterologous boosting, a person administered a different vaccine from the one that was used for the primary dose series.

iNCOVACC is the world's first intranasal vaccine for Covid to receive approval for a primary 2-dose schedule and heterologous booster dose, according to the statement.

The vaccine candidate was evaluated in Phases I, II and III clinical trials with successful results and has been specifically formulated to allow intranasal delivery through nasal drops, it said.

iNCOVACC had earlier received approval under Restricted Use in Emergency Situation for ages 18 and above for the primary 2-dose schedule. Phase III trials were conducted for safety, immunogenicity in 3100 subjects at 14 sites across the country.

Q2 GDP data to be released on November 30; SBI Research pegs growth at 5.8%